NCT06756269 2025-12-17To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 YearsShanghai Bovax Biotechnology Co., Ltd.Phase 2 Recruiting330 enrolled